Human glandular kallikrein 2: A potential serum marker for predicting the organ confined versus nonorgan confined growth of prostate cancer

Journal of Urology

Volumn 163, Issue 5, 2000, Pages 1491-1497

  Haese, Alexander ^a   Becker, Charlotte ^a   Noldus, Joachim ^a   Graefen, Markus ^a   Huland, Edith ^a   Huland, Hartwig ^a   Lilja, Hans ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Kallikrein II; Prostate; Prostate specific antigen; Prostatic neoplasms; Staging; Tumor

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TISSUE KALLIKREIN; TUMOR MARKER;

ADULT; ALGORITHM; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER LOCALIZATION; CANCER STAGING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RECEIVER OPERATING CHARACTERISTIC;

EID: 0034007660     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67649-5     Document Type: Article

References (39)

1. Esteve, J., Kricker, A., Ferlay, J. et al: Facts and Figures of Cancer in the European Community. Lyon, France: International Agency for Research on Cancer, p. 1, 1993
2. Hara, M., Koyanogi, Y., Inorre, T. et al: Some physio-chemical characteristics of "gamma-seminoprotein," an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. Jpn J Legal Med, 25: 322, 1971
3. Wang, M. C., Valenzuela, L. A., Murphy, G. P. et al: Purification of a human prostate specific antigen. Invest Urol, 17: 159, 1979
4. Catalona, W. J., Smith, D. S., Ratliff, T. J. et al: Measurement of prostate specific antigen in serum as a screening test for prostate cancer. New Engl J Med, 324: 1156, 1991
5. Oesterling, J. E.: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol, 145: 907, 1991
6. Partin, A. W. and Oesterling, J. E.: The clinical usefulness of prostate specific antigen: update 1994. J Urol, 152: 1358, 1994
7. Partin, A. W., Pound, C. R., Clemens, J. Q. et al: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin N Amer, 20: 713, 1993
8. Trapasso, J. G., deKernion, J. B., Smith, R. B. et al: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol, 152: 1821, 1994
9. Oesterling, J. E., Chan, D. W., Epstein, J. I. et al: Prostate specific antigen in preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol, 139: 766, 1988
10. Stamey, T. A., Kabalin, J. N., McNeal, J E. et al: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: II. Radical prostatectomy treated patients. J Urol, 141: 1076, 1989
11. Lange, P. H., Ercole, C. J., Lightner, D. J. et al: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol, 141: 873, 1989
12. Partin, A. W., Carter, H. B., Chan, D. W. et al: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol, 143: 747, 1990
13. Stamey,.T. A., Yang, N., Hay, A. R. et al: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med, 317: 909, 1987
14. Carter, H. B., Pearson, J. D., Metter, E. J. et al: Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA, 267: 2215, 1992
15. Benson, N. C., Whang, I. S., Olsson, C. A. et al: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol, part 2, 147: 817, 1992
16. Kalish, J., Adams, J., Cooner, W. H. et al: Comparison of PSAD and PSAT in benign and malignant prostatic disease. J Urol, suppl., 149: 414A, abstract 806, 1993
17. Oesterling, J. E., Jacobsen, S. J., Chute, C. G. et al: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA, 270: 860, 1993
18. Lilja, H., Christensson, A., Dahlén, U. et al: Prostate-specific antigen in serum occurs predominantly in complex with alpha-1 antichymotrypsin. Clin Chem, 37: 1618, 1991
19. Christensson, A., Björk, T., Nilsson, O. et al: Serum prostate specific antigen complexed to alpha-1 antichymotrypsin as an indicator of prostate cancer. J Urol, 150: 100, 1993
20. Stenman, U.-H., Leinonen, J., Alfthan, H. et al: A complex between prostate-specific antigen and alpha-1 antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res, 51: 222, 1991
21. Charlesworth, M. C., Young, C. Y., Klee, G. G. et al: Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. Urology, 49: 487, 1997
22. Darson, M F., Pacelli, A., Roche, P. et al: Human glandular kallikrein 2 (hk2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology, 49: 857, 1997
23. Saedi, M. S., Hill, T. M., Kuus-Reichel, K. et al: The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. Clin Chem, 44: 2115, 1998
24. Lilja, H.: Structure, function, and regulation of the enzyme activity of prostate-specific antigen. World J Urol, 11: 188, 1993
25. Young, C. F., Andrews, P. E., Montgomery, B. T. et al: Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry, 31: 818, 1992
26. Chapdelaine, P., Paradis, G., Tremblay, R. R. et al: High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett, 236: 205, 1988
27. Murtha, P., Tindall, D. J. and Young, C. Y.: Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5′promoter region of the gene. Biochemistry, 32: 6459, 1993
28. Lovgren, J., Rajakoski, K., Karp, M. et al: Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun, 238: 549, 1997
29. Finlay, J. A., Evans, C. L., Day, J. R. et al: Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology, 51: 804, 1998
30. Eerola, R., Piironen, T., Pettersson, K. et al: Immunoreactivity of recombinant human glandular kallikrein using monoclonal antibodies raised against prostate-specific antigen. Prostate, 31: 84, 1997
31. Corey, E., Buhler, K. R. and Vessella, R. L.: Cross-reactivity of ten anti-prostate-specific antigen monoclonal antibodies with human glandular kallikrein. Urology, 50: 567, 1997
32. Kwiatkowski, M. K., Recker, F., Piironen, T. et al: In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/ml. Urology, 52: 360, 1998
33. McNeal, J. E., Redwine, E. A., Freiha, F. S. et al: Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol, 12: 897, 1988
34. Gleason, D. F.: Histologic Grading and Clinical Staging of Prostate Carcinoma. In: Urologic Pathology: The Prostate. Edited by M. Tannenbaum. Philadelphia: Lea & Febiger, chapt. 7, pp. 171-197, 1977
35. Piironen, T., Lövgren, J., Karp, M. et al: Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem, 42: 1034, 1996
36. Catalona, W. J., Partin, A. W., Chan, D. W. et al: Detection of prostate cancer with %fPSA and hK2 when PSA is 2-4 ng/ml. J Urol, suppl., 161: 207, abstract 794, 1999
37. Lin, D. W., Ellis, W. J., Lange, P. H. et al: Serum human glandular kallikrein (hK2) in metastatic prostate cancer. J Urol, suppl., 161: 96, abstract 358, 1999
38. Becker, C., Lilja, H., Piironen, T. et al: HK2 measurements in a randomly selected population based screening for prostate cancer. J Urol, suppl., 161: 320, abstract 1233, 1999
39. Kwiatkowski, M., Recker, F., Piironen, T. et al: Various ratios of human glandular kallikrein (hK2) to free and total PSA improve discrimination between G1-G2 and G3 prostate tumors. J Urol, suppl., 161: 239, abstract 920, 1999